Microbicides and Their Role in HIV Prevention
Author Information
Author(s): Salim S. Abdool Karim, Cheryl Baxter
Primary Institution: Centre for the AIDS Program of Research in South Africa - CAPRISA, University of KwaZulu-Natal
Hypothesis
Can tenofovir gel effectively prevent HIV infection in women?
Conclusion
The CAPRISA 004 trial demonstrated that tenofovir gel can significantly reduce the risk of HIV infection in women.
Supporting Evidence
- Tenofovir gel reduced HIV acquisition by an estimated 39 percent overall.
- In high adherers, HIV incidence was 54 percent lower.
- Tenofovir gel was shown to be 51 percent effective in preventing Herpes simplex type 2 virus.
Takeaway
This study found that a special gel can help women avoid getting HIV when they have sex.
Methodology
A double-blind, randomized placebo-controlled trial assessing the effectiveness of a 1% vaginal gel formulation of tenofovir.
Limitations
Further studies are needed to confirm the findings and assess long-term effectiveness.
Participant Demographics
Rural and urban South African women aged 18 to 40 who were sexually active and HIV-negative.
Statistical Information
P-Value
0.017
Statistical Significance
p=0.017
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website